Summit Therapeutics plc : Grant of Share Options
Post# of 301275
Summit Therapeutics plc ("Summit", the "Company", or the "Group")
GRANT OF SHARE OPTIONS TO DIRECTORS/PDMRS
Oxford, UK, 12 April 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces the following option grants over new ordinary shares of 1p nominal value ('Ordinary Shares') were made on 11 April 2017 to Directors, PDMRs and employees in line with the Company's Long Term Incentive Plan.
Mr Glyn Edwards, the Company's Chief Executive Officer, was granted options over 762,764 Ordinary Shares. These options have an exercise price of 185 pence per share and will vest in full on 23 June 2019 subject to achievement of performance conditions pertaining to corporate and programme development milestones. This option award to Glyn Edwards was due to be made in 2016, during the Company's normal granting cycle, but was deferred due to insufficient headroom in the Company's Long Term Incentive Plan.
Dr David Roblin, the Company's Chief Operating Officer and President of Research and Development, was granted options over 324,324 Ordinary Shares. These options have an exercise price of 185 pence per share and will vest in full on 11 April 2020 subject to achievement of performance conditions pertaining to corporate and programme development milestones.
A further grant of options over 150,436 Ordinary Shares was made to other employees of the Company. These options will vest in nine equal tranches on a quarterly basis from 11 April 2018 and will vest in full on 11 April 2020.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: +44 (0)1235 443 951 +1 617 225 4455 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7213 0880 |
| N+1 Singer (Broker) Aubrey Powell / Lauren Kettle | Tel: +44 (0)20 7496 3000 |
| MacDougall Biomedical Communications (US media contact) Karen Sharma | Tel: +1 781 235 3060 ksharma@macbiocom.com |
| Consilium Strategic Communications (Financial public relations, UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville | Tel: +44 (0)20 3709 5700 summit@consilium-comms.com |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Mr Glyn Edwards | |||
| 2 | Reason for the notification | ||||
| a) | Position / status | Chief Executive Officer | |||
| b) | Initial notification / Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Summit Therapeutics plc | |||
| b) | LEI | 213800NRW8AOMYMTBD89 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 1 pence each | |||
| Identification code | GB00BN40HZ01 | ||||
| b) | Nature of the transactions | Grant of share options | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| 185 pence per share (exercise price) | 762,764 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | N/A | ||||
| - Price | |||||
| e) | Date of the transaction | 11 April 2017 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Dr David Roblin | |||
| 2 | Reason for the notification | ||||
| a) | Position / status | Chief Operating Officer and President of Research and Development | |||
| b) | Initial notification / Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Summit Therapeutics plc | |||
| b) | LEI | 213800NRW8AOMYMTBD89 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 1 pence each | |||
| Identification code | GB00BN40HZ01 | ||||
| b) | Nature of the transactions | Grant of share options | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| 185 pence per share (exercise price) | 324,324 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | N/A | ||||
| - Price | |||||
| e) | Date of the transaction | 11 April 2017 | |||
| f) | Place of the transaction | Outside a trading venue | |||
-END-
(0)
(0)